Loading stock data…
RPRX
$60.59-3.37 (-5.27%)
Market ClosedLast close Sep 8
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Royalty Pharma plc in the Healthcare sector is trading at $60.59 with a market capitalization of $31.2B. Wall Street consensus targets $65.12 (8 analysts), implying a +7.5% move over the next 12 months. The stock is currently near its 52-week high of $64.38, remaining 24.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +7.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $674.14M↑ | $630.58M↑ | $621.99M↑ | $609.29M↑ | $578.66M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $133.12M↓ | $632.48M↑ | $388.38M↓ | $427.16M↑ | $209.80M |
| Net Income | $17.88M↓ | $294.69M↑ | $214.21M↓ | $288.22M↑ | $32.18M |
Peer Comparison
JNJUNHPFE
Fundamentals
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-sta...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.12%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.01%
Volume
Today's trading volume
8.62M
Recent News
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history. Phase 3 HARBOR Trial Misses Primary Endpoint On Tuesday, the company shared data from the global Phase 3 HARBOR study evaluating del-desiran for myotonic dystrophy type 1 (DM1). The study did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia. Read Also: A Wall St
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough
On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights to future royalties on rusfertide, an experimental treatment for a rare blood disorder called polycythemia vera. It is Royalty Pharma’s second collaboration with Zealand, and it arrives just as rusfertide awaits a decision from the FDA. For a company […]
MRK, RPRX Stocks Hit 52-Week Highs – What Drove Today’s Gains?
Merck shares rose on growing confidence in its cancer pipeline, while Royalty Pharma hit a record high as Ziihera’s FDA approval strengthened its royalty opportunity.
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy targeted capital to harvest the long-term cash flows generated by those same drugs. A prime example unfolded when Royalty Pharma plc (NASDAQ:RPRX) acquired a […]
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?